title: Role of C5a in multiorgan failure during sepsis.
abstract: In humans with sepsis, the onset of multiorgan failure (MOF), especially involving liver, lungs, and kidneys, is a well known complication that is associated with a high mortality rate. Our previous studies with the cecal ligation/puncture (CLP) model of sepsis in rats have revealed a C5a-induced defect in the respiratory burst of neutrophils. In the current CLP studies, MOF occurred during the first 48 h with development of liver dysfunction and pulmonary dysfunction (falling arterial partial pressure of O(2), rising partial pressure of CO(2)). In this model an early respiratory alkalosis developed, followed by a metabolic acidosis with increased levels of blood lactate. During these events, blood neutrophils lost their chemotactic responsiveness both to C5a and to the bacterial chemotaxin, fMLP. Neutrophil dysfunction was associated with virtually complete loss in binding of C5a, but binding of fMLP remained normal. If CLP animals were treated with anti-C5a, indicators of MOF and lactate acidosis were greatly attenuated. Under the same conditions, C5a binding to blood neutrophils remained intact; in tandem, in vitro chemotactic responses to C5a and fMLP were retained. These data suggest that, in the CLP model of sepsis, treatment with anti-C5a prevents development of MOF and the accompanying onset of blood neutrophil dysfunction. This may explain the protective effects of anti-C5a in the CLP model of sepsis.
authors.affiliation: Department of Pathology University of Michigan Medical School, Ann Arbor, MI 48109, USA.
authors.forename: M
authors.initials: M
authors.lastname: Huber-Lang
authors.forename: V J
authors.initials: VJ
authors.lastname: Sarma
authors.forename: K T
authors.initials: KT
authors.lastname: Lu
authors.forename: S R
authors.initials: SR
authors.lastname: McGuire
authors.forename: V A
authors.initials: VA
authors.lastname: Padgaonkar
authors.forename: R F
authors.initials: RF
authors.lastname: Guo
authors.forename: E M
authors.initials: EM
authors.lastname: Younkin
authors.forename: R G
authors.initials: RG
authors.lastname: Kunkel
authors.forename: J
authors.initials: J
authors.lastname: Ding
authors.forename: R
authors.initials: R
authors.lastname: Erickson
authors.forename: J T
authors.initials: JT
authors.lastname: Curnutte
authors.forename: P A
authors.initials: PA
authors.lastname: Ward
mesh_terms: D000138:Acidosis / Q000276:immunology / Q000378:metabolism / Q000517:prevention & control; D000472:Alkalosis, Respiratory / Q000276:immunology / Q000517:prevention & control; D000595:Amino Acid Sequence; D000818:Animals; D002432:Cecum; D002634:Chemotaxis, Leukocyte; D015936:Complement C5a / Q000235:genetics / Q000276:immunology / Q000378:metabolism / Q000502:physiology*; D004591:Electrophoresis, Polyacrylamide Gel; D007106:Immune Sera / Q000494:pharmacology; D007457:Iodine Radioisotopes / Q000378:metabolism; D007668:Kidney / Q000473:pathology / Q000648:ultrastructure; D008026:Ligation; D008297:Male; D008969:Molecular Sequence Data; D009102:Multiple Organ Failure / Q000097:blood / Q000276:immunology* / Q000473:pathology; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000097:blood; D009504:Neutrophils / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D011485:Protein Binding / Q000235:genetics / Q000276:immunology; D051381:Rats; D020318:Rats, Long-Evans; D011994:Recombinant Proteins / Q000302:isolation & purification / Q000378:metabolism; D018805:Sepsis / Q000097:blood / Q000276:immunology* / Q000473:pathology; D014316:Tritium
chemical_list: D007106:Immune Sera; D007457:Iodine Radioisotopes; D011994:Recombinant Proteins; D014316:Tritium; D009240:N-Formylmethionine Leucyl-Phenylalanine; D015936:Complement C5a